Advertisement


Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

2023 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Efficacy of this regimen will be investigated in the second half of the study (Abstract TPS7589).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Muhit Özcan: Diffuse large B-cell lymphoma is typically treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, a regimen known as R-CHOP, but novel therapies are needed. A recent phase III study showed that replacing vincristine in R-CHOP with the antibody-drug conjugate polatuzumab vedotin was a viable approach in diffuse large B-cell lymphoma. ROR1 is an onco-fetal transmembrane protein that's expressed in a number of hematological malignancies, including diffuse large B-cell lymphomas. Zilovertamab vedotin is an antibody-drug conjugate comprising an anti-ROR1 antibody plus a cleavable linker, and the antimicrotubule cytotoxin monomethyl auristatin E, that has shown promising efficacy and manageable safety in patients with relapse or refractory hematological malignancies. The single-arm, open-label, phase II waveLINE-007 study has been designed to investigate zilovertamab vedotin in combination with R-CHP in patients with previously untreated diffuse like B cell lymphomas. Part one is being conducted to determine the safety and tolerability and recommended phase II dose of zilovertamab vedotin plus R-CHOP. Part two will be conducted to investigate the efficacy of zilovertamab vedotin plus R-CHP at the recommended phase II dose. The primary objectives of waveLINE-007 are to evaluate complete response rate based on Lugano criteria and to evaluate the safety and tolerability of zilovertamab vedotin plus R-CHP. Secondary objectives include evaluating objective response rate and the duration of response per Lugano criteria. Progression-free survival, overall survival, and the pharmacokinetics of zilovertamab vedotin plus R-CHP are exploratory. In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients will receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a minimum of 2.5 milligram per kilogram, with the target dose limiting toxicity rate of 30%. In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients with receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a maximum of 2.5 milligram per kilogram, with a target dose limiting toxicity rate of 30%. In the event of dose-limiting toxicities at the starting dose, the dose can also be deescalated to 1.5 milligram per kilogram. In part two, approximately 30 patients with received zilovertamab vedotin at the recommended phase II dose plus R-CHP intravenously every 3 weeks for six cycles or up to eight cycles for patients with high-risk disease. Eligible patients must be 18 years or older, have histologically confirmed diffuse large B cell lymphoma per WHO criteria, have PET-positive disease, have an ECOG performance status 0 or 1, and have an adequate organ function. Patients must not have received prior treatments for diffuse large B cell lymphoma patients with a history of transformation of indolent disease at diagnosis of primary mediastinal B-cell lymphoma, ongoing peripheral neuropathy of grade 2 or higher, or active central nervous system lymphoma will be excluded. Recruitment for waveLINE-007 is currently ongoing in Canada, Israel, Italy, Poland, Korea, Spain, and Turkey. Results from the waveLINE-007 study will provide insight into the efficacy and safety of zilovertamab vedotin plus R-CHP in patients with previously untreated diffuse large B-cell lymphomas.

Related Videos

Leukemia

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavily treated patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Manufacturing CD5 CAR T cells with tyrosine kinase inhibitors seemed to improve their potency and antitumor activity (Abstract 7002).

Lymphoma

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jennifer L. Crombie, MD, of Dana-Farber Cancer Institute, discusses the historically poor outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Her study examined real-world data on the use of novel therapies in this population and found that outcomes with second- and third-line regimens of polatuzumab vedotin-piiq plus bendamustine and rituximab and tafasitamab plus lenalidomide remain suboptimal, with worse outcomes particularly after chimeric antigen receptor T-cell therapy (Abstract 7552).

Lymphoma

Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma and prior BTK inhibitor therapy. Responses were observed in patients with high-risk disease features, including blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations (Abstract 7514).

Bladder Cancer
Immunotherapy

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).

Skin Cancer
Immunotherapy

Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716

Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up of 39.4 months, adjuvant pembrolizumab continued to show a benefit over placebo, with no new safety signals (Abstract LBA9505).

Advertisement

Advertisement




Advertisement